| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:27 | Isgro überzeugt Daiichi-Sankyo | 3 | new business | ||
| Do | AstraZeneca/Daiichi Sankyo's Enhertu shows promise in phase 3 breast cancer study | 8 | PMLiVE | ||
| 25.04. | Daiichi Sankyo GAAP EPS of ¥104.62 | 11 | Seeking Alpha | ||
| 09.04. | AstraZeneca, Daiichi Sankyo Drug Enhertu Becomes First Tumor-Agnostic ADC Cancer Med | 711 | MedCity News | ||
| 08.04. | AstraZeneca, Daiichi Sankyo's Enhertu wins historic HER2 tumor-agnostic FDA nod | 757 | FiercePharma | ||
| 08.04. | AstraZeneca/Daiichi Sankyo's Enhertu granted FDA accelerated approval for solid tumours | 392 | PMLiVE | ||
| 08.04. | FDA approves Daiichi Sankyo-AstraZeneca's Enhertu for solid tumours | 62 | Pharmaceutical Technology | ||
| 06.04. | Daiichi Sankyo: ENHERTU Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors | 1.670 | Business Wire | Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca's ENHERTU that showed clinically meaningful responses across a broad range of tumors
ENHERTU now has five approved indications... ► Artikel lesen | |
| 06.04. | FDA Approves AstraZeneca And Daiichi Sankyo's Enhertu For Solid Tumors Treatment | 2.184 | AFX News | LONDON (dpa-AFX) - The U.S. Food and Drug Administration approved AstraZeneca (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adult... ► Artikel lesen | |
| 03.04. | FDA accepts AstraZeneca-Daiichi Sankyo's Datopotamab deruxtecan BLA | 376 | Pharmaceutical Technology | ||
| 02.04. | FDA accepts Daiichi Sankyo-AstraZeneca's breast cancer therapy for review | 4 | Seeking Alpha | ||
| 02.04. | AZ, Daiichi Sankyo file Dato-DXd for second indication | 2 | pharmaphorum | ||
| 22.03. | Daiichi Sankyo: CHMP gibt positive Stellungnahmen für Bempedosäure und die Bempedosäure/Ezetimib-Kombinationstablette zur Behandlung von Hypercholesterinämie und zur signifikanten Verringerung kardiovaskulärer Ereignisse ab | 972 | Business Wire | Die positiven Stellungnahmen des CHMP beruhen auf den Analysen der Phase-3-Studie CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes. 1 ... ► Artikel lesen | |
| 22.03. | Daiichi Sankyo: CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed-dose combination tablet as treatments for hypercholesterolaemia and significantly reducing cardiovascular events | 472 | Business Wire | Positive CHMP opinions are based on the analyses of the Phase 3 CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes trial.1 European... ► Artikel lesen | |
| 13.03. | Daiichi Sankyo's Vanflyta approved by MHRA to treat acute myeloid leukaemia | 4 | PMLiVE | ||
| 12.03. | MHRA authorises Daiichi Sankyo quizartinib for AML for marketing | 5 | Pharmaceutical Technology | ||
| 07.03. | AstraZeneca/Daiichi Sankyo's Enhertu not recommended by NICE for advanced breast cancer | 7 | PMLiVE | ||
| 07.03. | UK NICE rejects Daiichi Sankyo's Enhertu for breast cancer | 5 | Pharmaceutical Technology | ||
| 04.03. | EMA awards double validation for Daiichi Sankyo and AstraZeneca's cancer ADC | 5 | Pharmaceutical Technology | ||
| 04.03. | EMA validates Daiichi Sankyo-AstraZeneca's cancer therapy applications | 3 | Pharmaceutical Business Review |
Seite:
1 2 3 4 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 5.534 |
| SUPER MICRO COMPUTER | 3.456 |
| BYD | 3.157 |
| BAYER | 3.079 |
| NEL | 2.604 |
| APPLE | 2.424 |
| NVIDIA | 2.300 |
| DEUTSCHE BANK | 2.219 |
| TUI | 2.188 |
| TESLA | 1.892 |
| MERCEDES-BENZ | 1.590 |
| PLUG POWER | 1.512 |
| AMAZON | 1.471 |
| VOLKSWAGEN | 1.422 |
| COMMERZBANK | 1.373 |
| AIXTRON SE | 1.260 |
| RHEINMETALL | 1.257 |
| RWE | 1.247 |
| NOVO NORDISK | 1.237 |
| DEUTSCHE LUFTHANSA | 1.201 |
| RENK GROUP | 1.173 |
| PAYPAL | 1.053 |
| BASF | 1.035 |
| DAIMLER TRUCK | 1.034 |
| SIEMENS ENERGY | 1.034 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
